Biosimilar Pipeline
Various (e.g., Breast Cancer with Pertuzumab biosimilar)
Range from Pre-clinical to Late-stageActive
Key Facts
Indication
Various (e.g., Breast Cancer with Pertuzumab biosimilar)
Phase
Range from Pre-clinical to Late-stage
Status
Active
Company
About Enzene Biosciences
Enzene Biosciences, founded in 2014 and headquartered in Alameda, USA, is an innovation-driven biotech and CDMO with a core focus on biosimilars and advanced manufacturing. Its key differentiator is the EnzeneX™ platform, a patented continuous bioprocessing technology designed to significantly lower production costs for complex biologics like monoclonal antibodies. The company operates a dual business model, offering end-to-end CDMO services to third parties while also developing its own pipeline of biosimilar products for licensing, positioning it to impact the global healthcare landscape through cost-effective biologics.
View full company profile